Cardiogenic shock complicating acute coronary syndromes

David Hasdai, Eric J. Topol, Robert M. Califf, Peter B. Berger, David Holmes

Research output: Contribution to journalReview article

127 Citations (Scopus)

Abstract

Cardiogenic shock remains the major cause of death among patients with all types of acute coronary syndromes. Thus, there is a growing interest in the identification of patients who are at risk for developing cardiogenic shock, in the exploration of different therapeutic approaches to preventing its development, and in the improvement of outcome when it occurs. This article reviews the aetiology and pathophysiology of cardiogenic shock, its epidemology, Its treatment (including pharmaceutical agents, counterpulsation, and revascularisation), and its outcome. Algorithms are presented that predict its occurrence in both ST-segment-elevation myocardial infarction and unstable angina or non-ST-elevation myocardial infarction, and that predict its mortality in patients with ST-segment-elevation acute myocardial infarction. Such new areas as metabolic therapy and glycopretein IIb/IIIa inhibitors are discussed, as are the economic implications of shock.

Original languageEnglish (US)
Pages (from-to)749-756
Number of pages8
JournalLancet
Volume356
Issue number9231
DOIs
StatePublished - Aug 26 2000

Fingerprint

Cardiogenic Shock
Acute Coronary Syndrome
Counterpulsation
Unstable Angina
Cause of Death
Shock
Therapeutics
Economics
Mortality
Pharmaceutical Preparations
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hasdai, D., Topol, E. J., Califf, R. M., Berger, P. B., & Holmes, D. (2000). Cardiogenic shock complicating acute coronary syndromes. Lancet, 356(9231), 749-756. https://doi.org/10.1016/S0140-6736(00)02640-4

Cardiogenic shock complicating acute coronary syndromes. / Hasdai, David; Topol, Eric J.; Califf, Robert M.; Berger, Peter B.; Holmes, David.

In: Lancet, Vol. 356, No. 9231, 26.08.2000, p. 749-756.

Research output: Contribution to journalReview article

Hasdai, D, Topol, EJ, Califf, RM, Berger, PB & Holmes, D 2000, 'Cardiogenic shock complicating acute coronary syndromes', Lancet, vol. 356, no. 9231, pp. 749-756. https://doi.org/10.1016/S0140-6736(00)02640-4
Hasdai, David ; Topol, Eric J. ; Califf, Robert M. ; Berger, Peter B. ; Holmes, David. / Cardiogenic shock complicating acute coronary syndromes. In: Lancet. 2000 ; Vol. 356, No. 9231. pp. 749-756.
@article{6843fd9b37fe4e0aa36750c9dbd07d61,
title = "Cardiogenic shock complicating acute coronary syndromes",
abstract = "Cardiogenic shock remains the major cause of death among patients with all types of acute coronary syndromes. Thus, there is a growing interest in the identification of patients who are at risk for developing cardiogenic shock, in the exploration of different therapeutic approaches to preventing its development, and in the improvement of outcome when it occurs. This article reviews the aetiology and pathophysiology of cardiogenic shock, its epidemology, Its treatment (including pharmaceutical agents, counterpulsation, and revascularisation), and its outcome. Algorithms are presented that predict its occurrence in both ST-segment-elevation myocardial infarction and unstable angina or non-ST-elevation myocardial infarction, and that predict its mortality in patients with ST-segment-elevation acute myocardial infarction. Such new areas as metabolic therapy and glycopretein IIb/IIIa inhibitors are discussed, as are the economic implications of shock.",
author = "David Hasdai and Topol, {Eric J.} and Califf, {Robert M.} and Berger, {Peter B.} and David Holmes",
year = "2000",
month = "8",
day = "26",
doi = "10.1016/S0140-6736(00)02640-4",
language = "English (US)",
volume = "356",
pages = "749--756",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9231",

}

TY - JOUR

T1 - Cardiogenic shock complicating acute coronary syndromes

AU - Hasdai, David

AU - Topol, Eric J.

AU - Califf, Robert M.

AU - Berger, Peter B.

AU - Holmes, David

PY - 2000/8/26

Y1 - 2000/8/26

N2 - Cardiogenic shock remains the major cause of death among patients with all types of acute coronary syndromes. Thus, there is a growing interest in the identification of patients who are at risk for developing cardiogenic shock, in the exploration of different therapeutic approaches to preventing its development, and in the improvement of outcome when it occurs. This article reviews the aetiology and pathophysiology of cardiogenic shock, its epidemology, Its treatment (including pharmaceutical agents, counterpulsation, and revascularisation), and its outcome. Algorithms are presented that predict its occurrence in both ST-segment-elevation myocardial infarction and unstable angina or non-ST-elevation myocardial infarction, and that predict its mortality in patients with ST-segment-elevation acute myocardial infarction. Such new areas as metabolic therapy and glycopretein IIb/IIIa inhibitors are discussed, as are the economic implications of shock.

AB - Cardiogenic shock remains the major cause of death among patients with all types of acute coronary syndromes. Thus, there is a growing interest in the identification of patients who are at risk for developing cardiogenic shock, in the exploration of different therapeutic approaches to preventing its development, and in the improvement of outcome when it occurs. This article reviews the aetiology and pathophysiology of cardiogenic shock, its epidemology, Its treatment (including pharmaceutical agents, counterpulsation, and revascularisation), and its outcome. Algorithms are presented that predict its occurrence in both ST-segment-elevation myocardial infarction and unstable angina or non-ST-elevation myocardial infarction, and that predict its mortality in patients with ST-segment-elevation acute myocardial infarction. Such new areas as metabolic therapy and glycopretein IIb/IIIa inhibitors are discussed, as are the economic implications of shock.

UR - http://www.scopus.com/inward/record.url?scp=0034718401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034718401&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)02640-4

DO - 10.1016/S0140-6736(00)02640-4

M3 - Review article

C2 - 11085707

AN - SCOPUS:0034718401

VL - 356

SP - 749

EP - 756

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9231

ER -